MA40687A - Méthodes et compositions de traitement de malformation vasculaire - Google Patents

Méthodes et compositions de traitement de malformation vasculaire

Info

Publication number
MA40687A
MA40687A MA040687A MA40687A MA40687A MA 40687 A MA40687 A MA 40687A MA 040687 A MA040687 A MA 040687A MA 40687 A MA40687 A MA 40687A MA 40687 A MA40687 A MA 40687A
Authority
MA
Morocco
Prior art keywords
compositions
treatment methods
vascular malformation
malformation treatment
vascular
Prior art date
Application number
MA040687A
Other languages
English (en)
Inventor
Elisabetta Dejana
Maria Grazia Lampugnani
Original Assignee
Ifom Fondazione St Firc Di Oncologia Molecolare
Univ Degli Studi Milano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ifom Fondazione St Firc Di Oncologia Molecolare, Univ Degli Studi Milano filed Critical Ifom Fondazione St Firc Di Oncologia Molecolare
Publication of MA40687A publication Critical patent/MA40687A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
MA040687A 2014-04-10 2015-04-09 Méthodes et compositions de traitement de malformation vasculaire MA40687A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14164118 2014-04-10

Publications (1)

Publication Number Publication Date
MA40687A true MA40687A (fr) 2017-03-28

Family

ID=50478259

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040687A MA40687A (fr) 2014-04-10 2015-04-09 Méthodes et compositions de traitement de malformation vasculaire

Country Status (12)

Country Link
US (1) US20170027896A1 (fr)
EP (1) EP3145547A1 (fr)
JP (1) JP2017513838A (fr)
KR (1) KR20160144459A (fr)
CN (1) CN106535937A (fr)
AU (1) AU2015245463A1 (fr)
BR (1) BR112016023519A2 (fr)
CA (1) CA2944600A1 (fr)
EA (1) EA201692038A1 (fr)
IL (1) IL248210A0 (fr)
MA (1) MA40687A (fr)
WO (1) WO2015155335A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3960181A3 (fr) * 2016-02-02 2022-06-01 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Substances chimiques et méthodes pour prévenir et traiter l'activation des fibroblastes médiée par le tgf-bêta, et pour combattre et traiter le cancer et la fibrose
JP2017214322A (ja) * 2016-05-31 2017-12-07 森永製菓株式会社 Ｇａｐｄｈ遺伝子発現増強剤及びｇａｐｄｈ遺伝子発現増強用食品組成物
WO2019086922A1 (fr) * 2017-10-31 2019-05-09 Université de Bourgogne Compositions thérapeutiques destinées à être utilisées dans le traitement d'états non malins associés à l'activation de la phosphatidylinositol-3-kinase : spectre hypertrophique, malformations capillaires cutanées et kératoses séborrhéiques
CN112980879B (zh) * 2021-02-23 2023-01-24 四川省人民医院 一种视网膜血管病变模型的构建方法及其应用
CN114107386B (zh) * 2021-11-29 2024-02-02 中国人民解放军军事科学院军事医学研究院 一种制备血脑屏障缺陷的小鼠模型的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
DE69740095D1 (de) * 1996-11-05 2011-02-17 Childrens Medical Center Thalidomide und Dexamethason für die Behandlung von Tumors
US6201028B1 (en) * 1998-12-08 2001-03-13 The Rockefeller University Methods and compositions for prevention and treatment of atherosclerosis and hyperlipidemia with non-steroidal anti-inflammatory drugs
US6303576B1 (en) * 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
FR2812812B1 (fr) * 2000-08-08 2002-10-11 Philippe Gorny Medicament destine notamment a combattre les dysfonctions sexuelles
EP2288378A4 (fr) 2008-04-16 2011-12-14 Univ Utah Res Found Ciblage pharmacologique de malformation vasculaire
US20110171193A1 (en) * 2008-06-12 2011-07-14 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating pulmonary hypertension
WO2010033581A1 (fr) * 2008-09-16 2010-03-25 University Of Washington Modulateurs moléculaires de la voie wnt/bêta-caténine
US20130274215A1 (en) * 2010-04-08 2013-10-17 Fate Therapeutics, Inc. Pharmaceutical compositions to treat fibrosis
CN103491772A (zh) 2011-04-01 2014-01-01 南方研究所 舒林酸衍生物、其用途及其制备

Also Published As

Publication number Publication date
EA201692038A1 (ru) 2017-05-31
KR20160144459A (ko) 2016-12-16
EP3145547A1 (fr) 2017-03-29
AU2015245463A1 (en) 2016-11-24
BR112016023519A2 (pt) 2018-03-13
JP2017513838A (ja) 2017-06-01
US20170027896A1 (en) 2017-02-02
CA2944600A1 (fr) 2015-10-15
CN106535937A (zh) 2017-03-22
WO2015155335A1 (fr) 2015-10-15
IL248210A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
IL283258A (en) A preparation for the treatment of hypothyroidism
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
IL252839A0 (en) Treatment of boils
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3590543T3 (da) Medicinsk forbinding
MA41119A (fr) Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
IL246791A0 (en) Compositions and methods for treating eye diseases
SG11201609652RA (en) Treatment of polybacterials infections
MA53882A (fr) Méthodes de traitement de la sclérose en plaques
IL249098A0 (en) Methods and preparations for the treatment of allergy and inflammatory diseases
DK3307267T3 (da) Behandling af multipel sklerose
DK3142664T3 (da) Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme
HK1244711A1 (zh) Hmgb1介導的炎症的治療
BR112018000204A2 (pt) métodos de tratamento de colite
SG11201701493VA (en) Systems level state characteristics in experimental treatment of disease
HK1255221A1 (zh) 使用卡多曲組合物進行治療的方法
MA40687A (fr) Méthodes et compositions de traitement de malformation vasculaire
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
DK3302478T3 (da) Pac-1 kombinations behandling
BR112016015712A8 (pt) método de tratamento de doenças hepáticas.
DK3233104T3 (da) Immunterapi-behandlinger og -sammensætninger
DK3200783T3 (da) Behandling af erytromelalgi
GB201515244D0 (en) Treatment of inflammatory disease or condition
DK3182980T3 (da) Behandling af glykosyleringsmangelsygdomme